Outstanding Scope of Anti-Obesity Drugs Market is Estimated to Grow Incredible CAGR till 2025 |Analysis by Top Key Vendors – Pfizer, Merck, F.Hoffmann-La Roche, GlaxoSmithKline

This report provides in depth study of “Anti-Obesity Drugs Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Anti-Obesity Drugs Market report also provides an in-depth survey of key players in the market organization.

Global Anti-Obesity Drugs Market overview:

BusinessIndustryReports have new report spread across 96 pages is an overview of the Global Anti-Obesity Drugs Market Report 2020. The Global Anti-Obesity Drugs Market is projected to grow at a healthy growth rate from 2020 to 2024 according to new research. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/265957

This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market. Anti-obesity drugs – both prescription and OTC – are of two main types: Centrally-acting drugs and peripherally-acting drugs. These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.

 On the basis of Product Type, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Prescription Drugs, OTC drugs.  Based on End Users/Applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including 6-18 Callant, 18-30 Adult, 30-60Middle-Aged.

Factors such as increasing prevalence of obesity, adoption of sedentary lifestyle, increasing aging population, and chronic nature of disease drive the market growth. However, side effects of the drugs and limited availability of combination therapy restrain the market growth. Moreover, introduction of novel anti-obesity drugs and untapped opportunities in emerging nations increase opportunities for the market growth during the forecast period.

Asia Pacific was a prominent market for Anti-Obesity Drugss in 2016. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income. Increased spending on home interiors is fuelling the Anti-Obesity Drugs market in Asia Pacific.

There are several manufacturers of Anti-Obesity Drugss in Europe and North America. In North America, the demand for Anti-Obesity Drugss is primarily driven by the residential sector. Improved standards of living and rising usage of Anti-Obesity Drugss for flooring purpose are anticipated to drive the market in North America.

In Europe, the demand for Anti-Obesity Drugs is anticipated to be primarily from the commercial sector. Anti-Obesity Drugss are being employed widely for flooring in commercial complexes, which is estimated be a major factor that is likely to propelling the consistent expansion of the Anti-Obesity Drugs market in the region.

Some of the major players that operate in the Global Anti-Obesity Drugs Market are Pfizer, Merck, F.Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eisai, Norgine, Arena Pharmaceuticals, Orexigen Therapeutics, Vivus, Alizyme, Rhythm Pharmaceuticals, Shionogi, Zafgan.

Latest Industry Updates:

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics. Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF) inhibitors.

More than 27 million Americans are living with OA, 11 million of whom have moderate-to-severe OA. Currently available treatment options for moderate-to-severe OA do not meet the needs of all patients, and many cycle through multiple therapies to find relief from their pain. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA to make a decision on the tanezumab application is in December 2020. In its acceptance letter, the FDA stated that it is currently planning to hold an Advisory Committee meeting to discuss this application.

"The FDA acceptance of the tanezumab application represents a significant milestone, and the breadth of our regulatory submission reflects the extensive clinical data we have gathered for tanezumab over the course of its development," said Ken Verburg, tanezumab development team leader, Pfizer Global Product Development. "There is an urgent need for innovation in the treatment of osteoarthritis, as there have been no new classes of medicines available for this debilitating condition in more than a decade. If approved, tanezumab would be a first-in-class treatment for patients suffering from chronic pain due to moderate-to-severe osteoarthritis who have experienced inadequate pain relief with other analgesics."

Buy Anti-Obesity Drugs Market analysis & forecast 2020-2024 Report along with complete TOC@ https://www.businessindustryreports.com/buy-now/265957/single

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of HD Map in these regions, from 2013 to 2024 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

Get Attractive Discount @ https://www.businessindustryreports.com/check-discount/265957

Table of Contents:

Section 1 Anti-Obesity Drugs Product Definition

Section 2 Global Anti-Obesity Drugs Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Anti-Obesity Drugs Shipments

2.2 Global Manufacturer Anti-Obesity Drugs Business Revenue

2.3 Global Anti-Obesity Drugs Market Overview

Section 3 Manufacturer Anti-Obesity Drugs Business Introduction

3.1 Pfizer Anti-Obesity Drugs Business Introduction

3.1.1 Pfizer Anti-Obesity Drugs Shipments, Price, Revenue and Gross profit 2014-2019

3.1.2 Pfizer Anti-Obesity Drugs Business Distribution by Region

3.1.3 Pfizer Interview Record

3.1.4 Pfizer Anti-Obesity Drugs Business Profile

3.1.5 Pfizer Anti-Obesity Drugs Product Specification

3.2 Merck Anti-Obesity Drugs Business Introduction

3.2.1 Merck Anti-Obesity Drugs Shipments, Price, Revenue and Gross profit 2014-2019

3.2.2 Merck Anti-Obesity Drugs Business Distribution by Region

3.2.3 Interview Record

3.2.4 Merck Anti-Obesity Drugs Business Overview

3.2.5 Merck Anti-Obesity Drugs Product Specification

3.3 F.Hoffmann-La Roche Anti-Obesity Drugs Business Introduction

3.3.1 F.Hoffmann-La Roche Anti-Obesity Drugs Shipments, Price, Revenue and Gross profit 2014-2019

3.3.2 F.Hoffmann-La Roche Anti-Obesity Drugs Business Distribution by Region

3.3.3 Interview Record

3.3.4 F.Hoffmann-La Roche Anti-Obesity Drugs Business Overview

3.3.5 F.Hoffmann-La Roche Anti-Obesity Drugs Product Specification

3.4 GlaxoSmithKline Anti-Obesity Drugs Business Introduction

3.5 AstraZeneca Anti-Obesity Drugs Business Introduction

3.6 Boehringer Ingelheim Anti-Obesity Drugs Business Introduction

Section 4 Global Anti-Obesity Drugs Market Segmentation (Region Level)

4.1 North America Country

4.1.1 United States Anti-Obesity Drugs Market Size and Price Analysis 2014-2019

4.1.2 Canada Anti-Obesity Drugs Market Size and Price Analysis 2014-2019

4.2 South America Country

4.2.1 South America Anti-Obesity Drugs Market Size and Price Analysis 2014-2019

TOC continue…..........................

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.